Lenalidomide in the Treatment of Chronic Lymphocytic Leukemia

Table 1

Selected clinical trials using lenalidomide alone for treatment of CLL. NR: not reported.

Study	Regimen	No. of patients	TLS all grades	TFR all grades	Hematologic side effects grade 3/4	OR (%)	CR (%)	OS (%)	PFS (%)
Chanan-Khanet al. [14] Phase II; relapsed/refractory CLL	5 mg/d escalated to 25 mg/d	45	5%	58%	Neutropenia 70% thrombocytopenia 45% anemia 18%	47	9	NR	NR
Ferrajoli et al. [6]; Phase II relapsed/refractory CLL	10 mg/d escalated to 25 mg/d	44	0	12%	Neutropenia 41% thrombocytopenia 15% anemia 3%	32	7	73 (with a median follow-up time of 14 months)	NR
Chen et al. [16]; Phase II untreated CLL	2.5 mg/descalated to 10 mg/d	25	0	88%	Neutropenia 72% thrombocytopenia 28% anemia 20%	56	0	92 (estimated 2 years OS)	89 (estimated 2 years PFS)
Aue et al. [17] Phase II; relapsed/refractory CLL	20 mg/d lowered to 10 mg/d	33	0	53%	Neutropenia 56% thrombocytopenia 30% anemia 15%	NR	NR	NR	NR
Badoux et al. [18]; phase II (elderly) untreated CLL	5 mg/d escalated to 25 mg/d	60	0	52%	Neutropenia 34% thrombocytopenia 12% anemia <1%	65	10	88 (estimated 2 years OS)	60 (estimated 2 years PFS)